GlassScriptPhysician profile
Carmen Carr
NPI 1679934624
$6,247.17
in general payments reported to CMS, 2019-2025
26 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,680 · 2023: $354 · 2024: $1,021 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,362 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.70 |
| Education | $205.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $3,812.09 | 2022-2025 | Auryxia, Vafseo |
| Novartis Pharmaceuticals Corporation | $351.97 | 2024-2025 | |
| Amgen INC. | $305.70 | 2024-2025 | Krystexxa, Tavneos, Aranesp |
| Calliditas Therapeutics US INC. | $209.24 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $206.87 | 2023-2025 | Acthar, Terlivaz |
| Opko Pharmaceuticals, LLC | $203.87 | 2023-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $173.80 | 2023-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $160.85 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $151.37 | 2023-2025 | Lokelma, Farxiga |
| Fresenius USA Marketing, INC. | $101.30 | 2023-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $85.66 | 2023-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $81.29 | 2024-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $72.78 | 2023-2025 | Purified Cortrophin Gel |
| Ardelyx, INC. | $44.43 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $43.41 | 2024 | Ultomiris |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $35.55 | 2025 | Empaveli |
| Vifor Pharma, INC. | $32.08 | 2025 | Veltassa |
| Takeda Pharmaceuticals U.S.A., INC. | $29.60 | 2024 | Livtencity |
| Genentech USA, INC. | $24.94 | 2025 | |
| Vanda Pharmaceuticals INC. | $22.59 | 2023 | Hetlioz, Fanapt |
| Novo Nordisk INC | $19.99 | 2025 | Ozempic |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.48 | 2025 | |
| Horizon Therapeutics Plc | $15.54 | 2023 | Krystexxa |
| Glaxosmithkline, LLC. | $14.98 | 2025 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.93 | 2025 | Jardiance |
| Boston Scientific Corporation | $13.86 | 2025 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.